Previous 10 | Next 10 |
- Mr. Craig Collard appointed to the Board of Directors - VANCOUVER , May 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potent...
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress Canada NewsWire VANCOUVER, May 14, 2020 - Momelotinib's demonstrable anemia benefit and low myelosuppressive potential...
Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis Canada NewsWire VANCOUVER, May 7, 20...
Sierra Oncology (NASDAQ: SRRA ): Q1 Non-GAAP EPS of -$1.31; GAAP EPS of -$3.14 misses by $0.40 . More news on: Sierra Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially affect overall MOMENTUM timelines - - Publications highlighting durability, safety, and efficacy data for momelotinib planned throughout 2020 ...
Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call Canada NewsWire VANCOUVER, Feb. 26, 2020 VANCOUVER , Feb. 26, 2020 /CNW/ - Sierra Oncology, Inc...
-"Building MOMENTUM for Patients with Myelofibrosis" scheduled for 10:00 a.m. ET on March 4, 2020 - VANCOUVER , Feb. 25, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, ...
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead Canada NewsWire VANCOUVER, Feb. 6, 2020 VANCOUVER , Feb. 6, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commerc...
Nano cap Sierra Oncology (NASDAQ: SRRA ) slumps 16% premarket on increased volume in reaction to its planned 1:40 reverse spli t of its common stock effective after the close today. Post-split trading will commence tomorrow, January 23, at the open. More news on: Sierra Oncolo...
Sierra Oncology Announces Reverse Stock Split Canada NewsWire VANCOUVER, Jan. 22, 2020 - Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...